Analysis of the efficacy and clinical application of ceritinib

Ceritinib is an ALK (anaplastic lymphoma kinase) inhibitor, a new generation of targeted therapy drugs, specifically used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). Compared with traditional chemotherapy drugs, ceritinib blocks the growth and spread of tumor cells by accurately identifying and inhibiting the abnormal signaling pathways caused by ALK gene mutations, and is highly specific and therapeutically targeted. Its clinical application provides a new treatment path for patients with ALK-positive advanced lung cancer. Especially for patients who fail or are intolerant to crizotinib, ceritinib has become an important follow-up drug option.

In terms of its mechanism of action, ceritinib can effectively inhibit the signaling driven by ALK fusion protein and prevent the rapid proliferation of cancer cells in the body. This mechanism determines its ability to control ALK-mutated tumors. Especially in patients with crizotinib resistance or brain metastasis, ceritinib has a stronger ability to penetrate the blood-brain barrier and can reach higher drug concentrations in brain tissue and delay tumor progression.

In clinical application, ceritinib is mainly used to treat patients with confirmed ALK-positive advanced non-small cell lung cancer, including patients who are resistant to crizotinib. Since ALK gene mutations are mainly found in adenocarcinoma patients in non-smokers or light smokers, and usually occur in younger people, this group of people is less sensitive to chemotherapy, so targeted therapy has become a core strategy. Ceritinib showed good progression-free survival and partial response rate in the early trial stage, and it was quickly approved by the US FDA and multiple national drug regulatory agencies.

Patients taking ceritinib must pass molecular testing ofALK fusion gene to determine the indication before taking the drug to ensure the effectiveness and safety of the targeted drug. Ceritinib is currently recommended to be taken with food to help improve bioavailability and reduce the risk of gastrointestinal discomfort.

Reference materials:https://go.drugbank.com/drugs/DB09063